glp 1 drug novo nordisk The U.S. Food and Administration (FDA) has issued a warning to over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications Buy More Save More:Triple Pack bundle_glow_up New Phase 3 retatrutide

glp 1 drug novo nordisk The U.S. Food and Administration (FDA) has issued a warning to over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications Buy More Save More:Triple Pack bundle_glow_up New Phase 3 retatrutide

New Phase 3 retatrutide data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats

Raises energy expenditure through controlled glucagon stimulation, encouraging the body to burn more fat

bundle_glow_up

Buy More Save More:Triple Pack

Drucker tells me that, anecdotally, he gets asked about this potential use a lot